North American Report

Chemotherapy-Induced Nausea and Vomiting Market to Witness Upsurge in Growth During the Forecast Period (2030) | Key Companies- Helsinn, Heron Therapeutics, Novartis, Acacia Pharma and Others

 Breaking News
  • No posts were found

Chemotherapy-Induced Nausea and Vomiting Market to Witness Upsurge in Growth During the Forecast Period (2030) | Key Companies- Helsinn, Heron Therapeutics, Novartis, Acacia Pharma and Others

October 20
03:48 2021
Chemotherapy-Induced Nausea and Vomiting Market to Witness Upsurge in Growth During the Forecast Period (2030) | Key Companies- Helsinn, Heron Therapeutics, Novartis, Acacia Pharma and Others
Delveinsight Business Research LLP
DelveInsight’s “Chemotherapy-Induced Nausea and Vomiting Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chemotherapy-Induced Nausea and Vomiting Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chemotherapy-Induced Nausea and Vomiting market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chemotherapy-Induced Nausea and Vomiting Market

Chemotherapy-Induced Nausea and Vomiting: An Overview

Chemotherapy Induced Nausea and Vomiting (CINV) is used to describe two of the most common and distressing side effects of cancer chemotherapy, i.e., nausea and vomiting. They cause a significant negative impact on the patients’ quality of life and on their ability to comply with therapy. Nausea and vomiting can also result in anorexia, decreased performance status, metabolic imbalance, wound dehiscence, esophageal tears, and nutritional deficiency.

Chemotherapy-Induced Nausea and Vomiting Market Key Facts

  • Among the CINV patients, female patients have more severe and frequent chemotherapy-induced nausea and vomiting than do male patients.

  • As per Ruggiero A et al. (2018), CINV has been estimated to occur in up to 70% of the paediatric population undergoing chemotherapy, which is similar to prevalence rates described in adult patients, for whom nausea and vomiting are described as the first and third most distressing chemotherapy adverse effects, with a prevalence of approximately 60% and 72%, respectively. 

Get FREE sample copy at: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market

Key Benefits of Chemotherapy-Induced Nausea and Vomiting Market Report

  • The report provides an in-depth analysis of Chemotherapy-Induced Nausea and Vomiting Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Chemotherapy-Induced Nausea and Vomiting Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Chemotherapy-Induced Nausea and Vomiting current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Chemotherapy-Induced Nausea and Vomiting market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Chemotherapy-Induced Nausea and Vomiting Market 

Chemotherapy-Induced Nausea and Vomiting market size is anticipated to increase during the study period, 2017–2030.  The key driver for the surge in market size is the rise in the number of incident cases in 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chemotherapy-Induced Nausea and Vomiting market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Chemotherapy-Induced Nausea and Vomiting market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Chemotherapy-Induced Nausea and Vomiting Epidemiology

The epidemiology section covers insights about the historical and current Chemotherapy-Induced Nausea and Vomiting patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Chemotherapy-Induced Nausea and Vomiting Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-Induced Nausea and Vomiting market or expected to get launched in the market during the study period. The analysis covers Chemotherapy-Induced Nausea and Vomiting market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Chemotherapy-Induced Nausea and Vomiting Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

The dynamics of Chemotherapy-Induced Nausea and Vomiting (CINV) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies.

Some of the key players in the Chemotherapy-Induced Nausea and Vomiting market includes:

  • Helsinn Healthcare

  • Heron Therapeutics

  • Novartis Therapeutics

  • Acacia Pharma and many others

Chemotherapy Induced Nausea and Vomiting Therapies covered in the report includes

  • APD403

  • Fosnetupitant IV

  • Fosnetupitant/palonosetron oral suspension (for pediatric patients)

And many others.

Request for Sample @ Chemotherapy-Induced Nausea and Vomiting Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Chemotherapy-Induced Nausea and Vomiting Competitive Intelligence Analysis

4. Chemotherapy-Induced Nausea and Vomiting Market Overview at a Glance

5. Chemotherapy-Induced Nausea and Vomiting Disease Background and Overview

6. Chemotherapy-Induced Nausea and Vomiting Patient Journey

7. Chemotherapy-Induced Nausea and Vomiting Epidemiology and Patient Population

8. Chemotherapy-Induced Nausea and Vomiting Treatment Algorithm, Current Treatment, and Medical Practices

9. Chemotherapy-Induced Nausea and Vomiting Unmet Needs

10. Key Endpoints of Chemotherapy-Induced Nausea and Vomiting Treatment

11. Chemotherapy-Induced Nausea and Vomiting Marketed Products

12. Chemotherapy-Induced Nausea and Vomiting Emerging Therapies

13. Chemotherapy-Induced Nausea and Vomiting Seven Major Market Analysis

14. Attribute Analysis

15. Chemotherapy-Induced Nausea and Vomiting Market Outlook (7 major markets)

16. Chemotherapy-Induced Nausea and Vomiting Access and Reimbursement Overview

17. KOL Views on the Chemotherapy-Induced Nausea and Vomiting Market.

18. Chemotherapy-Induced Nausea and Vomiting Market Drivers

19. Chemotherapy-Induced Nausea and Vomiting Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market

Latest Reports By DelveInsight

Dysfunctional Uterine Bleeding Market

DelveInsight’s “Dysfunctional Uterine Bleeding Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dysfunctional Uterine Bleeding market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Healthcare Blogs

Hearing Loss Market Analysis

Hearing Loss represents one of the significant challenges to the affected person. It affects personal and professional life and results in fewer educational and job opportunities. As per the World Health Organization, nearly 430 million people (representing over 5% of the world’s population) require rehabilitation to address their ‘disabling’ hearing loss. By 2050, over 700 million people, that is, one in every ten people globally will have disabling hearing loss. Treatment options including medications, surgery and hearing aid device are available in the Hearing Loss market. Globally, several leading companies in the therapeutics domain are actively working to further bridge the gap in the treatment. Read More: Hearing Loss Treatment Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/